Acceleron Pharma price target raised to $65 from $35 at Piper Jaffray Piper Jaffray raised its price target for Acceleron Pharma shares to $65 ahead of the clinical data read-outs it expects to start in June. Piper expects share value to be driven by the company's clinical progress for dalantercept, as it sees blockbuster potential in multiple cancers. The firm reiterates an Overweight rating on Acceleron.
News For XLRN From The Last 14 Days
Check below for free stories on XLRN the last two weeks.